6385 related articles for article (PubMed ID: 2818873)
1. Immunogenicity and tumor protective activity of B16 melanoma vaccines.
Johnston D; Bystryn JC
Mol Biother; 1989; 1(4):218-22. PubMed ID: 2818873
[TBL] [Abstract][Full Text] [Related]
2. Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens.
Bystryn JC
J Immunol; 1978 Jan; 120(1):96-101. PubMed ID: 627729
[TBL] [Abstract][Full Text] [Related]
3. Identification of immunogenic B16 melanoma-associated antigens.
Johnston D; Schachne JP; Bystryn JC
J Biol Response Mod; 1987 Apr; 6(2):108-20. PubMed ID: 3585408
[TBL] [Abstract][Full Text] [Related]
4. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
[TBL] [Abstract][Full Text] [Related]
6. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
8. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
9. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma.
Celik C; Lewis DA; Goldrosen MH
Cancer Res; 1983 Aug; 43(8):3507-10. PubMed ID: 6861123
[TBL] [Abstract][Full Text] [Related]
10. Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine.
Baral R; Mandal I; Chattopadhyay U
Int Immunopharmacol; 2005 Jul; 5(7-8):1343-52. PubMed ID: 15914339
[TBL] [Abstract][Full Text] [Related]
11. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
Stackpole CW; Demsey A
Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ
Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
14. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
15. Persistence of immunogenic pulmonary metastases in the presence of protective anti-melanoma immunity.
Donawho CK; Pride MW; Kripke ML
Cancer Res; 2001 Jan; 61(1):215-21. PubMed ID: 11196164
[TBL] [Abstract][Full Text] [Related]
16. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
18. [Immunopotentiation of novel adjuvant SWZY on the poorly immunogenic murine melanoma vaccine].
Zhou Y; Qi X; Xiao JX; Lai BC; Si LS; Wang YL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):526-9. PubMed ID: 16806024
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.
Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J
Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127
[TBL] [Abstract][Full Text] [Related]
20. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
